Tilray share price up 1% after Q4 earnings revenue beat

Tilray share price has risen after a positive earnings report. The Canadian marijuana company had high sales and worse-than-expected losses as well.

Tilray earnings:key figures

Tilray share price up 1% as earnings revenue beats estimates

Tilray’s Q4 revenue was $15.5 million, an astonishing 200% increase. Tilray’s revenue exceeded Wall Street’s prediction of $14.1 million. The cannabis company also had a sales surge of $43.1 million, a 110% growth. Purchases of kilograms of marijuana grew to 6,478 from 3,024 in 2017.

The corporation’s sales grew because of an increase in exports to the US and Europe. There was also a jump in sales in Canada, which recently legalised recreational marijuana. The marijuana company’s chief executive officer(CEO), Brendan Kennedy, said important changes led to an increase in Tilray’s profits.

‘Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,’ said Kennedy.

Though Tilray’s revenue grew, the corporation experienced large losses. The company had $31 million in losses, or $0.33 per share. That amount is twice what financial experts expected. The corporation blamed the losses on international expansion costs and operating expenses.

How did Tilray’s Q4 results compare to other marijuana stocks?

Compared to other marijuana companies like Aurora Cannabis. Tilray also had better-than-expected profits. Both Canadian pot companies also had large losses because of operating costs and declines in cannabis-related equities.

What’s next for Tilray’s Q1 profits?

Tilray offered strong guidance for Q1. Kennedy told investors how he expects Tilray’s revenue to increase in the future.

‘Longer term, we continue to expect 50% plus gross margins as we lower our costs through greenhouse and outdoor cultivation, and as we ramp those facilities past the start-up phase,’ said Kennedy.

‘We also expect reduced revenue per unit as selling wholesale and the adult-use market becomes a bigger mix of our revenues,’ added Kennedy.

Tilray benefits from a boom in pot sales

With a surge in marijuana use, Tilray has expanded its reach by partnering with Budweiser to develop cannabis-infused drinks. Kennedy believes that Tilray’s revenue can grow in the long run through strategic alliances.

‘We believe that over the long-term companies such as Tilray with the portfolio of trusted brands powered by multinational supply chain, will win the market by earning the confidence of patients, consumers and governments around the world,’ said Kennedy.